Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

Accord Healthcare Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom

Accord announces that the CHMP has issued a positive opinion for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immunology conditions.The approval of Imuldosa® further enhances Accord Healthcare's biosimilar portfolio and strengthens Accord's Autoimmune Franchise building on existing leading brands.Imuldosa® will be the 5th biosimilar for Accord in the EU, with a further 10 in various stages of development.View original content:https://www.prnewswire.co.uk/news-releases/accord-healthcare-receives-positive-chmp-opinion-for-imuldosa-a-ustekinumab-biosimilar-to-stelara-302280374.html